{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:46:16Z","timestamp":1794440776848,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12967-017-1348-8","type":"journal-article","created":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T12:19:58Z","timestamp":1512389998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6541-0997","authenticated-orcid":false,"given":"Silvana","family":"Morello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaelena","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Mallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio M.","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,4]]},"reference":[{"issue":"4","key":"1348_CR1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"5256","key":"1348_CR2","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734\u20136.","journal-title":"Science"},{"issue":"1","key":"1348_CR3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","volume":"1","author":"MJ Selby","year":"2013","unstructured":"Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1(1):32\u201342.","journal-title":"Cancer Immunol Res"},{"issue":"23","key":"1348_CR4","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1158\/1078-0432.CCR-09-2376","volume":"15","author":"A Ribas","year":"2009","unstructured":"Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res. 2009;15(23):7116\u20138.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"1348_CR5","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412\u201320.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1348_CR6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"21","key":"1348_CR7","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691\u20137.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1348_CR8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","volume":"4","author":"A Bertrand","year":"2015","unstructured":"Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;4(13):211.","journal-title":"BMC Med."},{"issue":"19","key":"1348_CR9","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845\u201355.","journal-title":"N Engl J Med"},{"issue":"3","key":"1348_CR10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(17)30015-3","volume":"18","author":"C Coens","year":"2017","unstructured":"Coens C, Suciu S, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol. 2017;18(3):393\u2013403.","journal-title":"Lancet Oncol."},{"issue":"7","key":"1348_CR11","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u201334.","journal-title":"J Exp Med"},{"issue":"29","key":"1348_CR12","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1200\/JCO.2009.27.2146","volume":"28","author":"ML Disis","year":"2010","unstructured":"Disis ML. Immune regulation of cancer. J Clin Oncol. 2010;28(29):4531\u20138.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1348_CR13","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"4","key":"1348_CR14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"issue":"1","key":"1348_CR15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"4","key":"1348_CR16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375\u201384.","journal-title":"Lancet Oncol."},{"issue":"34","key":"1348_CR17","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","volume":"31","author":"JS Weber","year":"2013","unstructured":"Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31(34):4311\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1348_CR18","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","volume":"21","author":"GT Gibney","year":"2015","unstructured":"Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015;21(4):712\u201320.","journal-title":"Clin Cancer Res"},{"key":"1348_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017. https:\/\/doi.org\/10.1056\/NEJMoa1709684 .","journal-title":"N Engl J Med"},{"issue":"11","key":"1348_CR20","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","volume":"17","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558\u201368.","journal-title":"Lancet Oncol."},{"key":"1348_CR21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017. https:\/\/doi.org\/10.1056\/NEJMoa1709030 .","journal-title":"N Engl J Med"},{"issue":"15","key":"1348_CR22","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600\u20139.","journal-title":"JAMA"},{"key":"1348_CR23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0663","author":"MK Chuk","year":"2017","unstructured":"Chuk MK, Chang JT, Theoret MR, Sampene E, He K, Weis SL, et al. FDA approval summary: accelerated approval of pembrolizumab for second-line treatment of metastatic melanoma. Clin Cancer Res. 2017. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0663 .","journal-title":"Clin Cancer Res"},{"issue":"19","key":"1348_CR24","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064\u201374.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1348_CR25","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1158\/1078-0432.CCR-15-0244","volume":"21","author":"JM Taube","year":"2015","unstructured":"Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Cancer Res. 2015;21(17):3969\u201376.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1348_CR26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/pcmr.12340","volume":"28","author":"J Madore","year":"2015","unstructured":"Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2015;28(3):245\u201353.","journal-title":"Pigment Cell Melanoma Res."},{"issue":"9","key":"1348_CR27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40265-016-0588-x","volume":"76","author":"L Festino","year":"2016","unstructured":"Festino L, Botti G, Lorigan P, Masucci GV, Hipp JD, Horak CE, et al. Cancer treatment with anti-PD-1\/PD-L1 agents: is PD-L1 expression a biomarker for patient selection? Drugs. 2016;76(9):925\u201345.","journal-title":"Drugs."},{"issue":"4","key":"1348_CR28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11912-016-0509-x","volume":"18","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Postow MA. Emerging tissue and blood-based biomarkers that may predict response to immune checkpoint inhibition. Curr Oncol Rep. 2016;18(4):21.","journal-title":"Curr Oncol Rep."},{"issue":"Suppl 3","key":"1348_CR29","first-page":"39","volume":"28","author":"KM Mahoney","year":"2014","unstructured":"Mahoney KM, Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park). 2014;28(Suppl 3):39\u201348.","journal-title":"Oncology (Williston Park)"},{"issue":"12","key":"1348_CR30","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrc3613","volume":"13","author":"L Antonioli","year":"2013","unstructured":"Antonioli L, Blandizzi C, Pacher P, Hask\u00f3 G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer. 2013;13(12):842\u201357.","journal-title":"Nat Rev Cancer"},{"key":"1348_CR31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fimmu.2016.00109","volume":"7","author":"A Ohta","year":"2016","unstructured":"Ohta A. A metabolic immune checkpoint: adenosine in tumor microenvironment. Front Immunol. 2016;7:109.","journal-title":"Front Immunol."},{"issue":"2","key":"1348_CR32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2217\/imt.15.106","volume":"8","author":"D Allard","year":"2016","unstructured":"Allard D, Allard B, Gaudreau PO, Chrobak P, Stagg J. CD73-adenosine: a next-generation target in immuno-oncology. Immunotherapy. 2016;8(2):145\u201363.","journal-title":"Immunotherapy."},{"issue":"34","key":"1348_CR33","doi-asserted-by":"crossref","first-page":"57327","DOI":"10.18632\/oncotarget.16905","volume":"8","author":"R Wang","year":"2017","unstructured":"Wang R, Zhang Y, Lin X, Gao Y, Zhu Y. Prognostic value of CD73-adenosinergic pathway in solid tumor: a meta-analysis and systematic review. Oncotarget. 2017;8(34):57327\u201336.","journal-title":"Oncotarget."},{"key":"1348_CR34","doi-asserted-by":"publisher","unstructured":"Huang Q, Durham NM, Sult E, Wu Y, Liu J, Holoweckyj N, et al. Levels and enzyme activity of CD73 in primary samples from cancer patients. In: Proceedings of the 106th annual meeting of the American Association for Cancer Research; 2015 Apr 18\u201322; Philadelphia. AACR; Cancer Res 2015;75 (15 Suppl): p. 1538. https:\/\/doi.org\/10.1158\/1538-7445.AM2015-1538 .","DOI":"10.1158\/1538-7445.AM2015-1538"},{"key":"1348_CR35","doi-asserted-by":"publisher","unstructured":"Hay C, Sult E, Huang Q, Hammond S, Mulgrew K, McGlinchey K, et al. MEDI9447: enhancing anti-tumor immunity by targeting CD73 In the tumor microenvironment. In: Proceedings of the 106th annual meeting of the American Association for Cancer Research; 2015 Apr 18\u201322; Philadelphia. Philadelphia: AACR; Cancer 2015;75(15 Suppl): p. 285. https:\/\/doi.org\/10.1158\/1538-7445.AM2015-285 .","DOI":"10.1158\/1538-7445.AM2015-285"},{"issue":"12","key":"1348_CR36","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1097\/CCM.0000000000000550","volume":"42","author":"M Maksimow","year":"2014","unstructured":"Maksimow M, Kyh\u00e4l\u00e4 L, Nieminen A, Kyl\u00e4np\u00e4\u00e4 L, Aalto K, Elima K, et al. Early prediction of persistent organ failure by soluble CD73 in patients with acute pancreatitis*. Crit Care Med. 2014;42(12):2556\u201364.","journal-title":"Crit Care Med"},{"issue":"6","key":"1348_CR37","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cellbi.2006.03.001","volume":"30","author":"N Nedeljkovic","year":"2006","unstructured":"Nedeljkovic N, Bjelobaba I, Subasic S, Lavrnja I, Pekovic S, Stojkov D, et al. Up-regulation of ectonucleotidase activity after cortical stab injury in rats. Cell Biol Int. 2006;30(6):541\u20136.","journal-title":"Cell Biol Int"},{"key":"1348_CR38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bcp.2016.05.006","volume":"112","author":"E Caiazzo","year":"2016","unstructured":"Caiazzo E, Maione F, Morello S, Lapucci A, Paccosi S, Steckel B, et al. Adenosine signalling mediates the anti-inflammatory effects of the COX-2 inhibitor nimesulide. Biochem Pharmacol. 2016;112:72\u201381.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"1348_CR39","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1080\/19420862.2016.1143182","volume":"8","author":"JC Geoghegan","year":"2016","unstructured":"Geoghegan JC, Diedrich G, Lu X, Rosenthal K, Sachsenmeier KF, Wu H, et al. Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action. MAbs. 2016;8(3):454\u201367.","journal-title":"MAbs."},{"issue":"36","key":"1348_CR40","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199\u2013206.","journal-title":"J Clin Oncol."},{"issue":"3","key":"1348_CR41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/01.cmr.0000215030.69823.11","volume":"16","author":"R Sadej","year":"2006","unstructured":"Sadej R, Spychala J, Skladanowski AC. Expression of ecto-5\u2019-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res. 2006;16(3):213\u201322.","journal-title":"Melanoma Res"},{"issue":"17","key":"1348_CR42","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1158\/0008-5472.CAN-17-0395","volume":"77","author":"J Reinhardt","year":"2017","unstructured":"Reinhardt J, Landsberg J, Schmid-Burgk JL, Ramis BB, Bald T, Glodde N, et al. MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy. Cancer Res. 2017;77(17):4697\u2013709.","journal-title":"Cancer Res"},{"issue":"9\u201311","key":"1348_CR43","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/15257770600894188","volume":"25","author":"R Sadej","year":"2006","unstructured":"Sadej R, Spychala J, Skladanowski AC. Ecto-5\u2019-nucleotidase (eN, CD73) is coexpressed with metastasis promoting antigens in human melanoma cells. Nucleosides Nucleotides Nucleic Acids. 2006;25(9\u201311):1119\u201323.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"8","key":"1348_CR44","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/bjc.2012.95","volume":"106","author":"H Wang","year":"2012","unstructured":"Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, et al. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer. 2012;106(8):1446\u201352.","journal-title":"Br J Cancer"},{"issue":"17","key":"1348_CR45","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1158\/0008-5472.CAN-17-0393","volume":"77","author":"A Young","year":"2017","unstructured":"Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, et al. Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis. Cancer Res. 2017;77(17):4684\u201396.","journal-title":"Cancer Res"},{"issue":"5","key":"1348_CR46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.116.021311","volume":"134","author":"H Liu","year":"2016","unstructured":"Liu H, Zhang Y, Wu H, D\u2019Alessandro A, Yegutkin GG, Song A, et al. Beneficial role of erythrocyte adenosine A2B receptor-mediated amp-activated protein kinase activation in high-altitude hypoxia. Circulation. 2016;134(5):405\u201321.","journal-title":"Circulation"},{"issue":"7","key":"1348_CR47","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","volume":"21","author":"L Liu","year":"2015","unstructured":"Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015;21(7):1639\u201351.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1348_CR48","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00109-013-1001-9","volume":"91","author":"M Sitkovsky","year":"2013","unstructured":"Sitkovsky M, Ohta A. Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer. J Mol Med (Berl). 2013;91(2):147\u201355.","journal-title":"J Mol Med (Berl)."},{"key":"1348_CR49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.07.002","volume":"76","author":"A Montinaro","year":"2013","unstructured":"Montinaro A, Iannone R, Pinto A, Morello S. Adenosine receptors as potential targets in melanoma. Pharmacol Res. 2013;76:34\u201340.","journal-title":"Pharmacol Res"},{"issue":"1","key":"1348_CR50","doi-asserted-by":"crossref","first-page":"e22448","DOI":"10.4161\/onci.22448","volume":"2","author":"R Sorrentino","year":"2013","unstructured":"Sorrentino R, Pinto A, Morello S. The adenosinergic system in cancer: key therapeutic target. Oncoimmunology. 2013;2(1):e22448.","journal-title":"Oncoimmunology."},{"issue":"1","key":"1348_CR51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev. 2017;276(1):121\u201344.","journal-title":"Immunol Rev"},{"key":"1348_CR52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.20517\/2394-4722.2017.29","volume":"3","author":"C Sorrentino","year":"2017","unstructured":"Sorrentino C, Morello S. Role of adenosine in tumor progression: focus on A2B receptor as potential therapeutic target. J Cancer Metastasis Treat. 2017;3:127\u201338.","journal-title":"J Cancer Metastasis Treat"},{"issue":"20","key":"1348_CR53","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-13-0545","volume":"19","author":"B Allard","year":"2013","unstructured":"Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res. 2013;19(20):5626\u201335.","journal-title":"Clin Cancer Res."},{"issue":"14","key":"1348_CR54","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1158\/0008-5472.CAN-14-0957","volume":"74","author":"D Mittal","year":"2014","unstructured":"Mittal D, Young A, Stannard K, Yong M, Teng MW, Allard B, et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 2014;74(14):3652\u20138.","journal-title":"Cancer Res"},{"issue":"2","key":"1348_CR55","first-page":"172","volume":"4","author":"R Iannone","year":"2014","unstructured":"Iannone R, Miele L, Maiolino P, Pinto A, Morello S. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am J Cancer Res. 2014;4(2):172\u201381.","journal-title":"Am J Cancer Res."},{"issue":"5","key":"1348_CR56","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","volume":"3","author":"PA Beavis","year":"2015","unstructured":"Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, et al. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res. 2015;3(5):506\u201317.","journal-title":"Cancer Immunol Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-017-1348-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T17:37:06Z","timestamp":1603474626000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-017-1348-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1348"],"URL":"https:\/\/doi.org\/10.1186\/s12967-017-1348-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"244"}}